Skip to main content
. 2017 Feb 23;19(8):1068–1078. doi: 10.1093/neuonc/now299

Fig. 6.

Fig. 6

Olig2 is required for DIPG proliferation. (A) Western blot showing Olig2 expression in serum-free DIPG4, JHH lines, and serum-dependent PBTR3 DIPG line. (B) Western blot showing Olig2 knockdown by Olig2 shRNA but not by control nontarget shRNA in DIPG4. (C‒F) Relative proliferation of PBTR3 serum line and serum-free SU-DIPG6, SU-DIPG4, and JHH-DIPG1 lines expressing nontarget or Olig2 shRNA. *P ≤ .005. Photomicrographs showing flank tumor formation in situ (G) or post resection (H) in Nu/Nu mice by CCHMC-DIPG1 serum-free line expressing nontarget shRNA or Olig2 shRNA. (I) NSG mice were imaged using the IVIS (Xenogen) system to monitor tumor growth at indicated days. (J) Kaplan‒Meier survival data of CCHMC-DIPG1 serum-free line expressing NT or Olig2 shRNA. *P = .0007.